Together, these results show that dual intron-targeting CRISPR-Cas9-mediated disruption of the oncogenic driver RUNX1-RUNX1T1 leads to a profound inhibition of AML t(8;21) cancer cell growth and proliferation in vitro. This evidence concerns the gene RUNX1 and acute myeloid leukemia.